Use and abuse of dissociative and psychedelic drugs in adolescence - PubMed
Review
Use and abuse of dissociative and psychedelic drugs in adolescence
M L Shawn Bates et al. Pharmacol Biochem Behav. 2021 Apr.
Abstract
Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage.
Keywords: Adolescence; Dissociatives; MDMA; Psychedelics; Reward.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Figures

Responses to subanesthetic doses of ketamine and phencyclidine in adolescent and adult male rats. A,C) Locomotor response to the first injection of ketamine (20 mg/kg) or phencyclidine (6 mg/kg) in PND 30, PND 38 or PND 60 animals. There is a descending response as animals age from early adolescence to adulthood. B, D) Sensitization to ketamine (20 mg/kg) or phencyclidine (6 mg/kg) in adolescent (JV) and adult (AD) male rats. Drug was injected once every three days for five total injections starting at PND 30 in adolescents or PND 60 in adults. An increase in response is seen in adults following repeated injection, while adolescents remain high (despite the influence of age, which should lead to a reduced response). Responses shown as horizontal locomotor counts. Redrawn from Rocha, Hart and Trujillo, 2017.
Similar articles
-
De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G. De Gregorio D, et al. J Neurosci. 2021 Feb 3;41(5):891-900. doi: 10.1523/JNEUROSCI.1659-20.2020. Epub 2020 Nov 30. J Neurosci. 2021. PMID: 33257322 Free PMC article. Review.
-
Jones GM, Nock MK. Jones GM, et al. J Psychopharmacol. 2022 Jan;36(1):46-56. doi: 10.1177/02698811211058923. Epub 2022 Jan 5. J Psychopharmacol. 2022. PMID: 34983249
-
Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C. Schipper S, et al. Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2. Cochrane Database Syst Rev. 2024. PMID: 39260823
-
Palamar JJ, Rutherford C, Le A, Keyes KM. Palamar JJ, et al. J Psychoactive Drugs. 2024 Sep-Oct;56(4):467-474. doi: 10.1080/02791072.2023.2240322. Epub 2023 Aug 21. J Psychoactive Drugs. 2024. PMID: 37605471
-
Le GH, Wong S, Badulescu S, Au H, Di Vincenzo JD, Gill H, Phan L, Rhee TG, Ho R, Teopiz KM, Kwan ATH, Rosenblat JD, Mansur RB, McIntyre RS. Le GH, et al. J Affect Disord. 2024 Jun 15;355:342-354. doi: 10.1016/j.jad.2024.03.165. Epub 2024 Apr 1. J Affect Disord. 2024. PMID: 38570038 Review.
Cited by
-
Jones G, Herrmann F, Wang E. Jones G, et al. Addict Behav Rep. 2023 Aug 12;18:100513. doi: 10.1016/j.abrep.2023.100513. eCollection 2023 Dec. Addict Behav Rep. 2023. PMID: 37649653 Free PMC article.
-
Psilocybin for Depression: From Credibility to Feasibility, What's Missing?
Munafò A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G. Munafò A, et al. Pharmaceuticals (Basel). 2022 Dec 31;16(1):68. doi: 10.3390/ph16010068. Pharmaceuticals (Basel). 2022. PMID: 36678564 Free PMC article.
-
Brain oxygen responses induced by opioids: focus on heroin, fentanyl, and their adulterants.
Kiyatkin EA, Choi S. Kiyatkin EA, et al. Front Psychiatry. 2024 Jan 17;15:1354722. doi: 10.3389/fpsyt.2024.1354722. eCollection 2024. Front Psychiatry. 2024. PMID: 38299188 Free PMC article. Review.
-
Gusmoes JD, Garcia-Cerde R, Valente JY, Pinsky I, Sanchez ZM. Gusmoes JD, et al. Subst Abuse Treat Prev Policy. 2022 Nov 1;17(1):71. doi: 10.1186/s13011-022-00496-w. Subst Abuse Treat Prev Policy. 2022. PMID: 36319981 Free PMC article.
-
Potential Therapeutic Effects of Psilocybin: A Systematic Review.
Goel DB, Zilate S. Goel DB, et al. Cureus. 2022 Oct 12;14(10):e30214. doi: 10.7759/cureus.30214. eCollection 2022 Oct. Cureus. 2022. PMID: 36381758 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical